NRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 0.3% - Time to Sell?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report)'s stock price was down 0.3% during trading on Monday . The stock traded as low as $3.33 and last traded at $3.37. Approximately 108,325 shares traded hands during trading, a decline of 74% from the average daily volume of 420,191 shares. The stock had previously closed at $3.38.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on NRXP shares. Wall Street Zen raised shares of NRx Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Ascendiant Capital Markets upped their price objective on shares of NRx Pharmaceuticals from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. HC Wainwright reaffirmed a "buy" rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, March 20th. BTIG Research initiated coverage on shares of NRx Pharmaceuticals in a research report on Wednesday, April 2nd. They issued a "buy" rating and a $18.00 price objective for the company. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $31.00 price objective on shares of NRx Pharmaceuticals in a research report on Friday, June 20th. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $28.50.

NRx Pharmaceuticals Stock Down 1.8%

The firm has a market capitalization of $55.50 million, a PE ratio of -1.60 and a beta of 1.59. The stock has a 50-day simple moving average of $2.90 and a 200-day simple moving average of $2.65.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. The business had revenue of $1.14 million for the quarter, compared to the consensus estimate of $1.14 million. Equities analysts forecast that NRx Pharmaceuticals, Inc. will post -1.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of NRXP. Anson Funds Management LP grew its stake in NRx Pharmaceuticals by 535.1% in the 1st quarter. Anson Funds Management LP now owns 1,179,061 shares of the company's stock valued at $2,417,000 after buying an additional 993,401 shares in the last quarter. AdvisorShares Investments LLC increased its holdings in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company's stock worth $683,000 after acquiring an additional 180,229 shares during the period. Millennium Management LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $61,000. Squarepoint Ops LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $56,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in NRx Pharmaceuticals during the 4th quarter worth approximately $33,000. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.